Though limited in number, the completed clinical trials of PARP inhibitors in advanced solid tumors and melanoma are providing valuable insights into the evolving landscape of targeted cancer therapies, which will inform both the personalization and expansion of treatment strategies in melanoma. This evidence concerns the gene PARP1 and cancer.